Jefferies Group’s Nektar Therapeutics NKTR Stock Holding History

Jefferies Group’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,747	Closed	-$99.6K	–	1843
2022 Q2	$99.6K	Sell	1,747 -4,100	-70%	-$259K	﹤0.01%	1355
2022 Q1	$473K	Buy	+5,847	New	+$865K	﹤0.01%	1072
2019 Q1	–	Sell	-2,540	Closed	-$1.25M	–	2533
2018 Q4	$1.25M	Buy	2,540 +667	+36%	+$403K	0.01%	1048
2018 Q3	$1.71M	Buy	1,873 +793	+73%	+$677K	0.01%	1057
2018 Q2	$791K	Buy	+1,080	New	+$1.25M	﹤0.01%	1376
2016 Q2	–	Sell	-3,420	Closed	-$705K	–	2344
2016 Q1	$705K	Buy	3,420 +3,267	+2,135%	+$628K	﹤0.01%	1286
2015 Q4	$39K	Hold	153	–	–	﹤0.01%	2140
2015 Q3	$25K	Hold	153	–	–	﹤0.01%	2149
2015 Q2	$29K	Sell	153 -5,547	-97%	-$955K	﹤0.01%	2563
2015 Q1	$941K	Buy	+5,700	New	+$1.17M	0.01%	1074
2013 Q4	–	Sell	-5,087	Closed	-$797K	–	2133
2013 Q3	$797K	Sell	5,087 -14,580	-74%	-$2.7M	0.01%	1010
2013 Q2	$3.41M	Buy	+19,667	New	+$3.02M	0.04%	339

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Jefferies Group's NKTR Position: Q2 2022 in Review

Jefferies Group sold out of Nektar Therapeutics (NKTR) in Q2 2022, closing a stake of 6,351 shares — an estimated $401K sold.

Jefferies Group first reported a position in NKTR in Q2 2013 and held it in 15 quarters. The position peaked at $2.93M in Q3 2018. 227 funds tracked by Wall St. Rank hold NKTR as of Q2 2022.

Jefferies Group reported no remaining Nektar Therapeutics position as of Q2 2022 after selling out during the quarter.
Jefferies Group sold 6,351 Nektar Therapeutics shares in Q2 2022, an estimated $401K.
Jefferies Group first reported a position in Nektar Therapeutics in Q2 2013 and held it in 15 quarters.
Jefferies Group's Nektar Therapeutics position peaked at $2.93M in Q3 2018.
227 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2022.

Based on Jefferies Group's 13F filing for Q2 2022, filed 15 Aug 2022.